As of 1 July, authorised psychiatrists have been allowed to prescribe MDMA to treat post-traumatic stress disorder, and psilocybin to treat depression that hasn’t responded to other treatment.

Psychedelic therapies have researchers excited because evidence suggests they might have lasting beneficial effects on factors that cause psychological distress beyond the treatment period. These include feeling disconnected from other people, fear of death, and rigid ways of thinking.